The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Sanjiv Chopra, MD: What Are the 5 Most Impactful Medical Science Advances for the Future?
Dr. Chopra described several key points of his Pri-Med Midwest presentation regarding the future of advances in medicine, including artificial intelligence, gut bacteria, and CRISPR technology.
Can Intranasal Corticosteroids Improve Obstructive Sleep Apnea Syndrome in Children?
A study featured at CHEST 2022 investigated INCS in children with OSAS to determine if the therapy improved their symptoms, polysomnography findings, behavior, and quality of life.
Pri-Med Midwest Highlights: Diabetes, Obesity Management & GLP-1 RAs
The emergence of weight loss agents like tirzepatide and an FDA Fast Track designation announced days earlier, endocrinologists were excited to discuss what's happening at Pri-Med Midwest 2022.
Pri-Med Midwest Highlights: Infectious Diseases, Colorectal Cancer, Adult Plaque Psoriasis
A highlighted description of some key takeaways from presentations at Pri-Med Midwest 2022, including such topics as infectious disease, monkeypox, colorectal cancer, psoriasis, and COVID-19.
Prevent, Treat Diabetes by Understanding the Basics of Obesity Management
As the age of diagnosis for pre and type 2 diabetes continues to decrease, Dr. Tina Thethi believes in focusing on reducing risk factors to prevent further complications.
Apremilast Also Addresses Manifestations of Psoriatic Arthritis
Dr. Veronica Anwuri discusses how apremilast (Otezla), the first oral, non biologic treatment option for plaque psoriasis can address the systemic pain associated with psoriatic arthritis.
Tirzepatide vs. Semaglutide: Tina Thethi, MD, Details the Differences Seen in Diabetes, Obesity
The ongoing buzz around GLP-1 RAs, like semaglutide, and now the GIP combination drug tirzepatide, reached a summit at Pri-Med Midwest 2022.
Tina Thethi, MD: GLP-1 RA Benefits Extend Beyond Diabetes, Obesity
"When you decrease the weight, that also improves the metabolic parameters. The A1c goes down, it helps bring the fasting glucose down, including even liver parameters," she explained.
Veronica Anwuri, MD: Benefits of Apremilast Treatment for Adult Plaque Psoriasis
An interview with Dr. Anwuri regarding her Pri-Med Midwest presentation on treating adult plaque psoriasis.
Frank Lavernia, MD, Discusses How Obesity Treatment is Changing
Semaglutide (Wegovy) has drawn attention for its indication of weight loss. Recently, however, the focus has shifted to the data surrounding tirzepatide.
Frank Lavernia, MD, Talks About the Reduced Risk of MACE With GLP-1 RAs
Despite the efforts to increase the affordability of GLP-1 receptor agonists cost-effectiveness is still a barrier for many patients living with diabetes looking for effective therapies.
Robert Kushner, MD: Treatment Options to Address Diabetes, Obesity
In an interview during Pri-Med Midwest, Dr. Kushner spoke about the benefits of treating obesity and diabetes synchronously.
Charles Vega, MD: Colorectal Cancer Screenings, Preventative Services
A discussion with Dr. Vega regarding colorectal cancer screenings, aspirin use recommendations, and the current state of healthcare.
Robert Kushner, MD: Addressing the Importance of Lifestyle With Patients Who Have Diabetes, Obesity
Primary Care Physicians (PCPs) play a crucial role in endorsing lifestyle counseling and facilitating integrative care for their patients.
Charles Vega, MD: Atrial Fibrillation, Risk Factors for Autosomal Dominant Polycystic Kidney Disease
An interview with Dr. Vega regarding atrial fibrillation and clinical manifestations for ADPKD.
Michael Angarone, DO: Virus Outbreaks, Treating Hepatitis C in Developing Countries
A discussion with Dr. Angarone regarding his presentation at Pri-Med Midwest, exploring the topic of treating infectious disease in developing countries.
Charles Vega, MD: Common Urgent Care Presentations, Acute Pain Concerns
A discussion regarding highlights from Dr. Charles Vega’s presentation on common urgent care presentations and concerns regarding acute pain.
Robert Kushner, MD: Why Aren't Weight Loss Agents Reaching Patients With Obesity?
"Less than 2 or 3% of individuals with obesity—who are candidates for pharmacotherapy—actually receive a medication," Dr. Robert Kushner explains in an interview.
Michael Angarone, DO: Monkeypox Infection, Public Awareness, and High-Risk Patients
Dr. Angarone highlighted several key takeaways from his presentation at Pri-Med Midwest.
Michael Angarone, DO: Emerging Infectious Diseases, Vector-Borne Viruses
A discussion regarding highlights from Dr. Michael Angarone’s presentation on emerging infectious diseases.
Robert Cionni, MD: Innovations in Drug Delivery for Glaucoma Treatment
The SpyGlass IOL platform showcased a 45% drop in mean intraocular pressure at 3 months in first-in-human glaucoma trial.
David Lally, MD: Insights into Safety Data on EYP-1901 for nAMD
Safety data of the bioerodible sustained delivery intravitreal anti-VEGF treatment indicate no ocular or systemic serious adverse events with mild adverse events.
David Boyer, MD: Significance of 24-Month Safety Data on Pegcetacoplan in GA
A discussion into safety data from the Phase 3 DERBY and OAKS trials on pegcetacoplan with Dr. Boyer at AAO 2022.
AI Algorithm May Help Identify Eligibility for Diabetic Retinopathy Clinical Trials
New data from AAO 2022 show how technology may refine a currently inefficient enrollment practice for retina disease assessment.
Caroline Baumal, MD: The Promising Durability of Faricimab for DME
Two-year results from YOSEMITE and RHINE suggest that the positive results of faricimab for DME in year one carried into second year. Dr. Caroline Baumal joins for an in-depth discussion on the findings.
Bevacizumab Linked to Greater ROP Retreatment than Ranibizumab
A real-world comparison of the anti-VEGF agents suggests certain doses are associated with more likelihood of retreatment.
Jennifer Lim, MD: Extended Durability in nAMD, DME Achieved with Faricimab
Faricimab treatment for both DME and nAMD was able to reliably get to 16 week dosing in 60% of eyes from YOSEMITE and RHINE and TENAYA and LUCERNE.
Proposed Aflibercept Biosimilar Provides Comparable Efficacy, Safety for DME
Findings from the INSIGHT study suggest MYL-1701P may provide a new anti-VEGF biosimilar option to patients with the common form of vision loss.
Faricimab Exhibits Durable Efficacy in nAMD Treatment in TENAYA and LUCERNE
The 48-week results suggest robust CST reduction and visual gains with faricimab up to every 16 week dosing, comparable with aflibercept ever 8-weeks.
Dilsher Dhoot, MD: Analysis of OTX-TKI Implant Shows Promise for Wet AMD Treatment
The data show 80% of patients were rescue-free up to 6 months with a single OTX-TKI implant injection.
2 Clarke Drive Cranbury, NJ 08512